Changes in Lung Cancer Treatment as a Result of the Coronavirus Disease 2019 Pandemic
Open Access
- 17 September 2020
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 6 (11) , 1805-1806
Abstract
Patients with cancer have higher mortality rates from coronavirus disease 2019 (COVID-19),1-4 particularly those with lung cancer.5 Therefore, efforts are ongoing to limit exposure of these patients to the health care system. As a result, the COVID-19 pandemic has changed cancer care provision, but the extent and type of these changes are unknown. The goal of this study was to evaluate the changes in lung cancer treatment during the COVID-19 pandemic.Keywords
This publication has 7 references indexed in Scilit:
- Faculty Opinions recommendation of Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.2020
- COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort studyThe Lancet Oncology, 2020
- Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital SystemCancer Discovery, 2020
- Faculty Opinions recommendation of Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.2020
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyThe Lancet, 2020
- Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 OutbreakCancer Discovery, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020